| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pathology, Surgical | 6 | 2020 | 12 | 1.480 |
Why?
|
| Breast Neoplasms | 12 | 2021 | 1118 | 1.410 |
Why?
|
| Pathology, Clinical | 6 | 2022 | 21 | 1.360 |
Why?
|
| Uterine Neoplasms | 4 | 2021 | 29 | 1.110 |
Why?
|
| Breast | 3 | 2019 | 174 | 0.900 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2021 | 12 | 0.870 |
Why?
|
| Cytodiagnosis | 3 | 2018 | 44 | 0.790 |
Why?
|
| Immunohistochemistry | 10 | 2021 | 851 | 0.770 |
Why?
|
| Schistosoma | 1 | 2019 | 3 | 0.670 |
Why?
|
| Schistosomiasis | 1 | 2019 | 4 | 0.670 |
Why?
|
| Calcinosis | 2 | 2019 | 79 | 0.650 |
Why?
|
| Mucin-1 | 2 | 2011 | 14 | 0.630 |
Why?
|
| Mesothelioma | 2 | 2011 | 27 | 0.620 |
Why?
|
| Diagnosis, Differential | 11 | 2021 | 934 | 0.510 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2022 | 135 | 0.500 |
Why?
|
| Biopsy | 4 | 2021 | 410 | 0.480 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2018 | 6 | 0.470 |
Why?
|
| Biomarkers, Tumor | 6 | 2021 | 461 | 0.470 |
Why?
|
| Ovarian Neoplasms | 4 | 2021 | 130 | 0.470 |
Why?
|
| Female | 43 | 2022 | 30772 | 0.450 |
Why?
|
| Research Design | 4 | 2018 | 556 | 0.450 |
Why?
|
| Pathologists | 4 | 2022 | 12 | 0.450 |
Why?
|
| Humans | 56 | 2022 | 59458 | 0.440 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2013 | 5 | 0.420 |
Why?
|
| Receptors, Estrogen | 4 | 2018 | 124 | 0.420 |
Why?
|
| Drug Therapy | 1 | 2013 | 52 | 0.400 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 45 | 0.400 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 71 | 0.400 |
Why?
|
| Vaginal Smears | 4 | 2009 | 54 | 0.380 |
Why?
|
| Desmin | 1 | 2011 | 5 | 0.380 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2011 | 10 | 0.380 |
Why?
|
| Epithelium | 1 | 2011 | 96 | 0.370 |
Why?
|
| Papanicolaou Test | 3 | 2009 | 42 | 0.370 |
Why?
|
| Pathology | 2 | 2009 | 11 | 0.360 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2011 | 51 | 0.360 |
Why?
|
| DNA Methylation | 3 | 2020 | 272 | 0.360 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 43 | 0.360 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2517 | 0.350 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2007 | 61 | 0.350 |
Why?
|
| Adenocarcinoma | 5 | 2008 | 323 | 0.350 |
Why?
|
| Endometrial Neoplasms | 3 | 2017 | 53 | 0.340 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2021 | 17 | 0.340 |
Why?
|
| Bartonella henselae | 1 | 2009 | 2 | 0.320 |
Why?
|
| Cat-Scratch Disease | 1 | 2009 | 2 | 0.320 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2009 | 9 | 0.310 |
Why?
|
| Testicular Neoplasms | 2 | 2021 | 32 | 0.300 |
Why?
|
| Cystitis | 1 | 2008 | 9 | 0.300 |
Why?
|
| Urinary Bladder | 1 | 2008 | 38 | 0.290 |
Why?
|
| Middle Aged | 18 | 2021 | 16336 | 0.290 |
Why?
|
| Mediastinal Neoplasms | 1 | 2007 | 17 | 0.290 |
Why?
|
| Mediastinum | 1 | 2007 | 27 | 0.280 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2007 | 1 | 0.280 |
Why?
|
| Adult | 18 | 2021 | 15698 | 0.280 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2007 | 55 | 0.280 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2007 | 31 | 0.270 |
Why?
|
| Carcinoma | 2 | 2018 | 116 | 0.270 |
Why?
|
| Enteric Nervous System | 1 | 2006 | 4 | 0.260 |
Why?
|
| Hirschsprung Disease | 1 | 2006 | 6 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2006 | 8 | 0.260 |
Why?
|
| Ganglion Cysts | 1 | 2006 | 4 | 0.260 |
Why?
|
| Immunoenzyme Techniques | 1 | 2006 | 107 | 0.260 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2005 | 51 | 0.260 |
Why?
|
| Breast Diseases | 1 | 2006 | 39 | 0.260 |
Why?
|
| Pleural Neoplasms | 1 | 2006 | 19 | 0.250 |
Why?
|
| Genes, p53 | 2 | 2003 | 52 | 0.250 |
Why?
|
| Trichomonas vaginalis | 1 | 2005 | 8 | 0.250 |
Why?
|
| Pons | 1 | 2005 | 15 | 0.250 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2005 | 18 | 0.250 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 584 | 0.250 |
Why?
|
| Aged | 14 | 2021 | 13424 | 0.240 |
Why?
|
| BK Virus | 1 | 2005 | 24 | 0.240 |
Why?
|
| Artifacts | 1 | 2006 | 125 | 0.240 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2005 | 68 | 0.240 |
Why?
|
| Polyomavirus Infections | 1 | 2005 | 46 | 0.240 |
Why?
|
| Cerebellum | 1 | 2005 | 91 | 0.240 |
Why?
|
| Diagnostic Errors | 3 | 2015 | 94 | 0.230 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 101 | 0.230 |
Why?
|
| Vulvar Diseases | 1 | 2004 | 5 | 0.230 |
Why?
|
| Adenosarcoma | 2 | 2021 | 4 | 0.230 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2004 | 16 | 0.230 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 339 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2011 | 194 | 0.220 |
Why?
|
| Stereotaxic Techniques | 1 | 2003 | 29 | 0.220 |
Why?
|
| CpG Islands | 3 | 2020 | 211 | 0.210 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 359 | 0.210 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 134 | 0.210 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 49 | 0.200 |
Why?
|
| Genes, BRCA1 | 1 | 2002 | 16 | 0.200 |
Why?
|
| Ligases | 1 | 2002 | 26 | 0.200 |
Why?
|
| Internship and Residency | 2 | 2009 | 748 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2005 | 205 | 0.200 |
Why?
|
| DNA-Binding Proteins | 4 | 2018 | 1151 | 0.190 |
Why?
|
| Granular Cell Tumor | 1 | 2021 | 1 | 0.190 |
Why?
|
| Granulosa Cell Tumor | 1 | 2021 | 5 | 0.190 |
Why?
|
| Nuclear Proteins | 4 | 2018 | 750 | 0.190 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2010 | 62 | 0.190 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 5126 | 0.190 |
Why?
|
| Gene Amplification | 1 | 2021 | 23 | 0.190 |
Why?
|
| Research Report | 2 | 2022 | 26 | 0.190 |
Why?
|
| Urine | 2 | 2014 | 38 | 0.180 |
Why?
|
| Carcinosarcoma | 1 | 2021 | 6 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 300 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2010 | 289 | 0.180 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2020 | 2 | 0.180 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2002 | 210 | 0.180 |
Why?
|
| Adolescent | 7 | 2011 | 5851 | 0.170 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 302 | 0.170 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 36 | 0.160 |
Why?
|
| Cervix Uteri | 3 | 2022 | 56 | 0.160 |
Why?
|
| Endodermal Sinus Tumor | 2 | 2020 | 3 | 0.160 |
Why?
|
| Transcriptome | 3 | 2018 | 343 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2013 | 354 | 0.150 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 104 | 0.140 |
Why?
|
| Endometrium | 2 | 2017 | 28 | 0.140 |
Why?
|
| Transcription Factors | 3 | 2018 | 1471 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2009 | 1794 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 652 | 0.140 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 448 | 0.140 |
Why?
|
| Mammography | 1 | 2019 | 271 | 0.140 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2014 | 59 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 496 | 0.130 |
Why?
|
| Smooth Muscle Tumor | 1 | 2016 | 1 | 0.130 |
Why?
|
| Loss of Heterozygosity | 3 | 2010 | 24 | 0.130 |
Why?
|
| Leiomyomatosis | 1 | 2016 | 3 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 1513 | 0.130 |
Why?
|
| Vascular Neoplasms | 1 | 2016 | 16 | 0.130 |
Why?
|
| Communication | 1 | 2020 | 547 | 0.120 |
Why?
|
| Infant | 3 | 2009 | 1493 | 0.120 |
Why?
|
| Carcinoma in Situ | 2 | 2007 | 33 | 0.120 |
Why?
|
| Decision Making | 1 | 2018 | 395 | 0.120 |
Why?
|
| Obesity | 1 | 2022 | 1167 | 0.120 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2014 | 7 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2014 | 29 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 248 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2008 | 71 | 0.110 |
Why?
|
| Male | 9 | 2021 | 27790 | 0.110 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 79 | 0.110 |
Why?
|
| Testis | 1 | 2014 | 136 | 0.110 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 27 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 28 | 0.110 |
Why?
|
| Axilla | 1 | 2013 | 15 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 59 | 0.100 |
Why?
|
| Trans-Activators | 2 | 2018 | 300 | 0.100 |
Why?
|
| Mastectomy, Segmental | 1 | 2013 | 45 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 1028 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 186 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2013 | 215 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 1097 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 4 | 2010 | 868 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 70 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2009 | 6079 | 0.090 |
Why?
|
| Hyperplasia | 1 | 2011 | 85 | 0.090 |
Why?
|
| Time Factors | 1 | 2018 | 3621 | 0.090 |
Why?
|
| Guidelines as Topic | 2 | 2017 | 154 | 0.090 |
Why?
|
| Animals | 6 | 2019 | 19678 | 0.080 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2010 | 29 | 0.080 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2009 | 2 | 0.080 |
Why?
|
| Peritoneal Lavage | 1 | 2009 | 4 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 70 | 0.080 |
Why?
|
| Prognosis | 2 | 2018 | 1597 | 0.080 |
Why?
|
| Silver Staining | 1 | 2009 | 5 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 443 | 0.080 |
Why?
|
| Lymphadenitis | 1 | 2009 | 4 | 0.080 |
Why?
|
| Uterine Cervical Diseases | 1 | 2009 | 4 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 24 | 0.080 |
Why?
|
| Serologic Tests | 1 | 2009 | 34 | 0.080 |
Why?
|
| Child | 2 | 2009 | 4201 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 152 | 0.080 |
Why?
|
| Neoplasms | 1 | 2018 | 1233 | 0.080 |
Why?
|
| Struma Ovarii | 1 | 2008 | 2 | 0.070 |
Why?
|
| Vulvar Neoplasms | 1 | 2008 | 9 | 0.070 |
Why?
|
| Urinary Bladder Fistula | 1 | 2008 | 2 | 0.070 |
Why?
|
| Metaplasia | 1 | 2008 | 18 | 0.070 |
Why?
|
| Urinalysis | 1 | 2008 | 30 | 0.070 |
Why?
|
| Genital Neoplasms, Female | 1 | 2008 | 17 | 0.070 |
Why?
|
| Lipoma | 1 | 2008 | 17 | 0.070 |
Why?
|
| Choristoma | 1 | 2008 | 22 | 0.070 |
Why?
|
| Endometriosis | 1 | 2008 | 24 | 0.070 |
Why?
|
| Cysts | 1 | 2008 | 40 | 0.070 |
Why?
|
| Antigens, Bacterial | 1 | 2009 | 200 | 0.070 |
Why?
|
| Adenoma | 1 | 2008 | 64 | 0.070 |
Why?
|
| Intestinal Neoplasms | 1 | 2007 | 13 | 0.070 |
Why?
|
| Papilloma | 1 | 2007 | 12 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 2 | 2020 | 46 | 0.070 |
Why?
|
| DNA, Bacterial | 1 | 2009 | 260 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 167 | 0.070 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2007 | 16 | 0.070 |
Why?
|
| Thigh | 1 | 2007 | 26 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2009 | 188 | 0.070 |
Why?
|
| Mucins | 1 | 2007 | 25 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2009 | 283 | 0.070 |
Why?
|
| Myenteric Plexus | 1 | 2006 | 2 | 0.070 |
Why?
|
| Submucous Plexus | 1 | 2006 | 2 | 0.070 |
Why?
|
| Vacuum | 1 | 2006 | 7 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2009 | 1560 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 284 | 0.060 |
Why?
|
| Australasia | 2 | 2018 | 6 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2007 | 677 | 0.060 |
Why?
|
| Rectum | 1 | 2006 | 86 | 0.060 |
Why?
|
| United Kingdom | 2 | 2018 | 66 | 0.060 |
Why?
|
| JC Virus | 1 | 2005 | 23 | 0.060 |
Why?
|
| Fallopian Tube Diseases | 1 | 2005 | 5 | 0.060 |
Why?
|
| Cytoplasmic Granules | 1 | 2005 | 51 | 0.060 |
Why?
|
| International Cooperation | 2 | 2018 | 84 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2005 | 76 | 0.060 |
Why?
|
| Myxoma | 1 | 2005 | 13 | 0.060 |
Why?
|
| Canada | 2 | 2018 | 147 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2005 | 117 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2005 | 58 | 0.060 |
Why?
|
| Colon | 1 | 2006 | 136 | 0.060 |
Why?
|
| United States | 4 | 2018 | 7432 | 0.060 |
Why?
|
| Young Adult | 3 | 2009 | 4274 | 0.060 |
Why?
|
| Astrocytes | 1 | 2005 | 116 | 0.060 |
Why?
|
| Vinblastine | 1 | 2004 | 18 | 0.060 |
Why?
|
| Etoposide | 1 | 2004 | 33 | 0.060 |
Why?
|
| alpha-Mannosidase | 1 | 2004 | 5 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2014 | 2902 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2014 | 65 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2005 | 120 | 0.050 |
Why?
|
| Fiber Optic Technology | 1 | 2003 | 24 | 0.050 |
Why?
|
| Carbohydrates | 1 | 2004 | 39 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2004 | 77 | 0.050 |
Why?
|
| Genes, p16 | 1 | 2003 | 6 | 0.050 |
Why?
|
| Radiographic Image Enhancement | 1 | 2003 | 98 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2004 | 239 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 398 | 0.050 |
Why?
|
| Government Agencies | 1 | 2022 | 10 | 0.050 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2002 | 6 | 0.050 |
Why?
|
| Brain Diseases | 1 | 2003 | 71 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2002 | 38 | 0.050 |
Why?
|
| Mitosis | 1 | 2004 | 209 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 52 | 0.050 |
Why?
|
| Paget Disease, Extramammary | 1 | 2002 | 2 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2002 | 54 | 0.050 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2021 | 2 | 0.050 |
Why?
|
| Alleles | 1 | 2003 | 411 | 0.050 |
Why?
|
| Contrast Media | 1 | 2003 | 404 | 0.040 |
Why?
|
| North America | 1 | 2021 | 105 | 0.040 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2020 | 2 | 0.040 |
Why?
|
| Biomarkers | 1 | 2006 | 1306 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 182 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 5 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2020 | 14 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2020 | 53 | 0.040 |
Why?
|
| Neurons | 1 | 2005 | 865 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 474 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 193 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 118 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 720 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 54 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2003 | 2377 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 396 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2016 | 24 | 0.030 |
Why?
|
| Leiomyoma | 1 | 2016 | 15 | 0.030 |
Why?
|
| Hysterectomy | 2 | 2009 | 65 | 0.030 |
Why?
|
| Laboratories | 1 | 2015 | 27 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Serine | 1 | 2014 | 84 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2007 | 3241 | 0.030 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2013 | 4 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 2458 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 365 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 62 | 0.030 |
Why?
|
| Mice | 4 | 2010 | 10309 | 0.030 |
Why?
|
| Transfection | 1 | 2014 | 675 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 383 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2011 | 5 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 885 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 210 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 428 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 590 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 152 | 0.020 |
Why?
|
| Milk, Human | 1 | 2011 | 88 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1505 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 942 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2010 | 21 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 19 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 30 | 0.020 |
Why?
|
| Keratins | 1 | 2010 | 30 | 0.020 |
Why?
|
| Reference Standards | 1 | 2010 | 71 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 71 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 161 | 0.020 |
Why?
|
| Conization | 1 | 2009 | 2 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 108 | 0.020 |
Why?
|
| Omentum | 1 | 2009 | 12 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2010 | 101 | 0.020 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2009 | 28 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2011 | 391 | 0.020 |
Why?
|
| Telepathology | 1 | 2009 | 6 | 0.020 |
Why?
|
| Parity | 1 | 2009 | 71 | 0.020 |
Why?
|
| Photography | 1 | 2009 | 40 | 0.020 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Goiter | 1 | 2008 | 9 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2008 | 31 | 0.020 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 2007 | 23 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2009 | 338 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2007 | 53 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2007 | 87 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2007 | 77 | 0.020 |
Why?
|
| Mammary Glands, Animal | 1 | 2007 | 78 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 85 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 295 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2011 | 850 | 0.020 |
Why?
|
| Prolapse | 1 | 2005 | 3 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 608 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2006 | 196 | 0.020 |
Why?
|
| Genotype | 1 | 2007 | 619 | 0.020 |
Why?
|
| Survival Rate | 1 | 2007 | 801 | 0.010 |
Why?
|
| Karyotyping | 1 | 2004 | 44 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2004 | 52 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2004 | 105 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2009 | 683 | 0.010 |
Why?
|
| Plant Lectins | 1 | 2004 | 7 | 0.010 |
Why?
|
| Acetylglucosamine | 1 | 2004 | 10 | 0.010 |
Why?
|
| Galactose | 1 | 2004 | 12 | 0.010 |
Why?
|
| Lactose | 1 | 2004 | 11 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 157 | 0.010 |
Why?
|
| Heterozygote | 1 | 2004 | 162 | 0.010 |
Why?
|
| Carbohydrate Metabolism | 1 | 2004 | 48 | 0.010 |
Why?
|
| Inbreeding | 1 | 2003 | 5 | 0.010 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2003 | 12 | 0.010 |
Why?
|
| Plant Proteins | 1 | 2004 | 81 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 450 | 0.010 |
Why?
|
| Chromosomes | 1 | 2004 | 135 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 1368 | 0.010 |
Why?
|
| Estradiol | 1 | 2004 | 247 | 0.010 |
Why?
|
| DNA Repair | 1 | 2004 | 242 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 185 | 0.010 |
Why?
|
| DNA Damage | 1 | 2004 | 279 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 443 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 196 | 0.010 |
Why?
|
| Pregnancy | 1 | 2009 | 2215 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2002 | 96 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 428 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 1999 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 4990 | 0.010 |
Why?
|